Description: Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Home Page: www.akebia.com
245 First Street
Cambridge,
MA
02142
United States
Phone:
617 871 2098
Officers
| Name | Title |
|---|---|
| Mr. John P. Butler MBA | CEO, President & Director |
| Dr. Steven Keith Burke M.D. | Senior VP of Research & Development and Chief Medical Officer |
| Mr. Erik John Ostrowski M.B.A. | Senior VP, CFO & Chief Business Officer |
| Mr. Richard C. Malabre | Chief Accounting Officer |
| Ms. Kimberly Garko | Senior VP & Chief Technical Officer |
| Ms. Tracey Vetterick | Vice President of Portfolio Strategy & Corporate Administration |
| Mercedes Carrasco | Senior Director of Investor & Corporate Communications |
| Ms. Carolyn Rucci | Senior VP of Legal, General Counsel & Secretary |
| Ms. Meredith Bowman | Senior VP & Chief People Officer |
| Mr. Nicholas Grund | Senior VP & Chief Commercial Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.7193 |
| Price-to-Sales TTM: | 2.468 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 167 |